Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lacosamide - UCB

Drug Profile

Lacosamide - UCB

Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 11 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; Duke University; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine NMDA-associated antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Generalised seizures; Tonic-clonic epilepsy
  • Phase II/III Epilepsy
  • Phase II Seizures
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Pain; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 08 Jan 2019 Registered for Partial epilepsies (Adjunctive treatment, In children, In adolescents) in Japan (PO)
  • 08 Jan 2019 Registered for Partial epilepsies (In children, In adolescents, Monotherapy) in Japan (PO)
  • 03 Dec 2018 Registered for Partial epilepsies (Adjunctive treatment, In adults, In adolescents) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top